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Introduction
Serum prostate-specific antigen (PSA) assay is broadly
used to screen for prostate cancer in men over the age
of 50 years. PSA level > 4 ng/mL is an indication for
prostate biopsy. However, about 20–30% of cancers
might not be detected in biopsy specimens that are
taken during the initial biopsy.1
Many have tried to improve the detection rate of
prostate cancer from prostate biopsy. For example,
Gore et al suggested a 10-core biopsy strategy.2 This
protocol has improved the cancer detection rate by
25.5% without significant morbidity.3 Other studies
have reported that the cancer detection rate can be
significantly improved by lowering the PSA cut-off
value to 2.5 ng/mL, or by evaluating the ratio of free
PSA to total PSA.4 However, many patients with high
suspicion of cancer are suggested to have repeat biop-
sies.5 Urologists are commonly consulted about how
many biopsies are adequate to confirm or rule out a
diagnosis of prostate cancer, especially in men with
rising PSA levels.
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The present study was performed to investigate the
natural history of a cohort of patients who had under-
gone at least 1 transrectal ultrasound-guided (TRUS)
prostate biopsy. The patients chose to have repeated
TRUS biopsy or transurethral resection of the prostate
(TURP) or just a follow-up policy at office visits.
Among these patients, we compared the characteristics
of biopsy methods in cancer detection rate.
Methods
We retrospectively reviewed 2,996 consecutive cases
who had undergone TRUS biopsy in our institution
between January 2000 and May 2005. Indications for
biopsy included serum PSA > 4.0 ng/mL or abnormal
digital rectal examination (DRE).
All transrectal biopsies were performed with a
spring-lodged autonomic biopsy gun equipped with
an 18-gauge Tru-Cut biopsy needle (C.R. Bard Inc.,
Covington, USA; length of sample notch: 1.9 cm),
under the guidance of an ultrasound scanner (7 MHz
biplane-probe; B-K Medical A/S, Herlev, Denmark).
Specimens were taken by the 6-core biopsy protocol,
and suspected nodules were taken separately under
finger-guided biopsy.
Prostate volume was calculated by the ellipsoid
prostate formula (width × length × height × 0.52). PSA
density was calculated by dividing total PSA value by
prostate volume. When the biopsy results were negative
for malignancy, patients were advised to have their PSA
level measured at follow-up 3 months later, and if PSA
remained elevated, repeat biopsy was suggested. Patients
with voiding difficulty, evaluated by the International
Prostate Symptom Score (IPSS) and urine flow rates,
were advised to undergo TURP. The TURP procedure
was comprised of removing the adenoma from the
transitional zone and the resection plane advanced to
the surgical capsule.
In patients without obstructive symptoms, PSA
values were regularly measured at 3- to 6-month inter-
vals. If any abnormality (either change in PSA or DRE)
was encountered, patients were recommended to have
another biopsy or TURP. The endpoint of the study
was defined as: (1) when a diagnosis of cancer was made,
by either TRUS biopsy or TURP; (2) when TURP was
completed.
All statistical analyses were performed using SPSS
version 11.0.1 (SPSS Inc., Chicago, IL, USA) for Win-
dows. Comparison of the cumulative detection rate of
prostate cancer diagnosed by TRUS biopsy and TURP
was obtained using the Kaplan-Meier method. The
differences in newly diagnostic detection rate of each
session between TRUS biopsy and TURP were evalu-
ated using the χ2 test. Mann-Whitney U test was used
to evaluate the significance of the differences between
these 2 groups in the second and third sessions.
Results
The median age of the 2,996 men was 74 years
(range, 24–99 years). Stratifying by indications for
biopsy, we found that 1,035 (34.5%) had PSA >
10 ng/mL, 1,549 (51.7%) had PSA between 4 and
10 ng/mL, and 412 (13.8%) had PSA < 4 ng/mL but
with suspicious DRE.
A total of 768 (25.6% of total included cases)
patients were diagnosed to have prostate cancer during
the study period. The cumulative prostate cancer detec-
tion rate by TRUS biopsy was 24.2% (724 of 2,996).
The individual detection rates in each individual
TRUS biopsy session were 22.9% (685 of 2,996) in the
first session, 8.7% (32 of 366) in the second session,
6.1% (6 of 98) in the third, 0% (0 of 29) in the fourth,
8.3% (1 of 12) in the fifth, 0% (0 of 5) in the sixth, and
0% (0 of 1) in the seventh (Figure 1).
In patients who received TURP, the cumulative
cancer detection rate was 10.4% (44 of 422). The
individual detection rate was 9.3% (35 of 375) in the
second session, 17.1% (6 of 35) in the third session,
18.2% (2 of 11) in the fourth, 0% (0 of 0) in the fifth,
and 100% (1 of 1) in the sixth session. The mean
prostate specimen weight resected by TURP was 25.2g
(range, 5–108 g).
Although the results showed no statistically signif-
icant difference in the cumulative cancer detection
rate by TRUS biopsy or TURP, there was a trend that
cancer detection rate by TURP was greater than that
by TRUS biopsy, especially in the second and third
sessions of diagnosis (Figure 2).
In the first session (TRUS biopsy only), a total of
685 cancers (22.9%) were found (685 of 2,996 men).
By stratifying the cancer detection rate according to
serum PSA levels, malignancy was detected in 14.8%
(61/412) of patients with PSA < 4 ng/mL, while it was
detected in 13.7% (212/1,549) of patients with PSA
4–10ng/mL, and in 41% (412/1,035) of patients with
PSA > 10 ng/mL. In the second session, there was no
significant difference in cancer detection rate between
the TRUS biopsy and TURP methods across different
PSA ranges (PSA < 4 ng/mL, 3.3% vs. 9%; PSA 4–10
ng/mL, 6.1% vs. 6.6%; PSA > 10 ng/mL, 14.5% vs.
11.9%; Table 1).
In prostate cancer patients, there was no differ-
ence in the demographic characteristics (age, prostate
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volume, PSA density) between the TRUS biopsy and
TURP methods (Table 2). In addition, serum PSA
levels before each session of assessment were examined.
We found no difference between patients who had
TRUS biopsy and TURP for the second session
(21.3 ± 40.7 vs. 19.7 ± 34.5, p = 0.85). However, the
PSA levels before biopsy were lower in patients who
underwent TURP than in those who had TRUS biopsy
in the third session (16.9±9.8 vs. 8.4±5.8, p<0.05). We
also found that Gleason grades were significantly lower
in TURP-diagnosed cancer than those detected tran-
srectally (for the second session, 6.7 ± 1.0 vs. 5.9 ± 1.5,
Mann-Whitney U test, p = 0.007; after the second 
session, 7.6 ± 1.3 vs. 5.2 ± 1.0, p = 0.002).
Of the patients who chose follow-up only, 6.3%
had their PSA increase by more than 50% of their 
initial values, 25% had their PSA levels drop back to
the normal range, and 66% had their PSA levels fluctu-
ate within 50% of their initial values at the end of the
study.
Discussion
The cancer detection rate of 1-time TRUS prostate
biopsy ranges from 22% to 34%.1,6 The rate found in
this study (22.9%) fits within that range. However,
single-session sextant biopsy might miss at least 20–30%
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Figure 1. Flowchart of patients receiving diagnostic sessions.
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of detectable prostate cancer.7 Thus, repeated biopsies
are necessary when indicated. Roehl et al reported that
cancer detection rates were 34% on the first TRUS
biopsy, 19% on the second biopsy, 8% on the third
biopsy, and 7% on the fourth biopsy.1 Durkan and
Greene reported that 31% (15 of 48) of the prostate
cancers diagnosed in their patients was from speci-
mens taken during second- or third-session sextant
biopsy.8 In our study, the cumulative cancer detection
rate (Figure 2) by both TRUS biopsy and TURP was
estimated to be approximately 98% during the first 
2 sessions. The prostate cancer detection rate by TRUS
biopsy in our study was 22.9% in the first session 
and 8.7% in the second session. Although the cancer
detection rate from the first biopsy was similar to that
reported in the literature, the positive rate in the second
biopsy in our study was much lower than that shown
in other studies. This finding might be due to the fact
that some of our patients chose to receive TURP rather
than undergo repeat TRUS biopsy. The other possi-
bility is that the biopsy protocol used in this study was
systemic sextant biopsy as proposed by Hodge et al.9,10
Although a 10-core or 12-core biopsy strategy increases
the cancer detection rate, it was reported in a prospec-
tive randomized trial comparing 6 versus 12 prostate
biopsy cores that the overall cancer detection rate was
not materially increased by 12-core biopsy.11,12 We
examined another patient cohort (n=474) who received
a 12-core biopsy protocol to compare the prostate can-
cer detection rate. The detection rate was 30.6% in the
first session, which was similar to previous reports.12,13
Although an increase of 7.7% in detection rate was
observed, the percentage of “significant” prostate
cancer did not show any significant difference between
the 6-core and 12-core biopsy groups (58.4% vs. 59.3%,
respectively, unpublished data).14
Some studies have emphasized lowering the PSA
cut-off value from 4.0 ng/mL to 2.5 ng/mL in order
to increase the cancer detection rate. For example,
Catalona et al reported that men with PSA levels of
2.5–4.0 ng/mL had an appreciable prevalence (22%)
of detectable cancer.15 However, data for Asian or
Chinese people are lacking in the English literature.
In our study, we noted that the repeat TRUS biopsy
rate decreased dramatically after the second session.
Furthermore, the ethnic characteristic of our patients
(100% Han Chinese) might also explain the discrepant
findings, such as decrease of prostate cancer detection
by the TRUS procedure in the second session.
Presti et al advocated performing biopsy with a
minimum of 8 cores, and increasing the number of
cores taken at the lateral aspect of the peripheral zone.7
Epstein et al, who performed sextant biopsies and
posterolateral needle biopsies on 150 radical prostatec-
tomy specimens, also support the importance of taking
biopsy for the lateral prostate. They determined that
maximum cancer detection results from combining
both techniques.16 Stewart et al proposed using a sat-
uration needle biopsy technique under anesthesia in
the operating room.17 They took additional biopsy
cores from the transition zone and detected prostate
cancer in 96% of the specimens taken during the first
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Figure 2. Cumulative cancer detection curves of the different biopsy methods.
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2 biopsy sessions. However, the complication rate was
high (12%), and urinary retention occurred in 4.5% of
the patients.
In addition, the choice of TURP procedure was due
to obstructive symptoms rather than randomization.
Furthermore, not all patients underwent repeated
TRUS biopsy or TURP after negative TRUS biopsies.
Therefore, it is difficult to demonstrate the real sensi-
tivity or specificity of TRUS biopsy. Actually, most
patients in the follow-up group had fluctuating PSA
levels. These patients might have had only latent cancers
of low clinical significance or other benign disorders
that contributed to their serum PSA levels.
It is still not easy to answer how many biopsies a
patient should undergo. We found that patients with
consistently negative biopsy results show a higher rate
of malignancy after subsequent TURP; this finding is
also reported in other studies.18–22 This might be
because tissue removed by TURP is chiefly from the
transition zone. In our study, after the third session,
cancer detection rate increased steeply in the TURP
group. This finding implies that we should focus on
tissue from the transition zones in patients with negative
findings from the second and third TRUS biopsies.
Therefore, for patients with repeated negative biopsy
results, TURP should be offered as an alternative when
there is a high suspicion of cancer.
Epstein et al demonstrated in a 10-year study that
benign biopsy specimens are more likely to be obtained
from larger prostate glands or from patients when can-
cer is located in the anterior region of the transitional
zone or the lateral regions.23 Philip et al also empha-
sized the importance of targeting the anterior zone in
transurethral biopsies or resections.18 Based on those
findings, Kitamura et al suggested using TURP for
detecting cancer in patients with peripheral zone and
transitional zone biopsy specimens that are negative
for malignancy.24 In particular, they reported that the
prostate cancer diagnosed from TURP specimens is
usually organ-confined. Interestingly, in our study, can-
cers detected by TURP had lower Gleason grades and
were associated with lower PSA levels than cancers
detected by TRUS biopsy, especially in later sessions.
This implies that the proportion of latent cancer might
be higher among these patients who had previous
negative TRUS biopsy results (Table 2). In our study,
patients receiving TURP did not have larger prostate
glands than those who had TRUS biopsy only (see
Table 2).
In conclusion, for patients who have had 2 negative
biopsies, TURP should be considered as an alternative
option for biopsy. However, if these patients do not
present with obstructive symptoms and are reluctant
to undergo TURP, then these patients could be man-
aged with observation, including monitoring of serum
PSA or undergo additional TRUS biopsy of tissue at
the transition zone. From our data, 3 consecutive biopsy
procedures may be indicated for high-risk patients.
Since very little benefit can be expected from fourth
or further TRUS biopsies, TURP biopsy is an alternative
diagnostic procedure for patients with persistently
high PSA and for those with comorbid illnesses such
as obstructive symptoms.
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